ع
Johnson & Johnson announced on July 28, 2026 a proposal to pay as much as 5.5 billion dollars to address the bulk of its remaining talc-related litigation. The offer targets around 69,000 cases involving allegations that the company’s baby powder and similar products led to ovarian cancer in users. Erik Haas, vice president of litigation at Johnson & Johnson, said the company decided to settle to put the matter behind it even though it believes the claims lack foundation. Haas added that the firm remained confident it would have succeeded in the majority of trials based on prior outcomes.
The proposed agreement requires approval from firms representing 95 percent of the ovarian cancer claims filed in both state and federal courts before it can proceed. According to plaintiffs’ leadership in the multidistrict litigation, the uncapped settlement is expected to deliver at least 5.5 billion dollars to roughly 70,000 affected women and families. Payments would begin with up to 3 billion dollars next year and feature no additional outlays prior to 2028, Johnson & Johnson detailed. The deal resolves approximately 99.75 percent of the outstanding talc claims, according to reports citing the settlement terms.
Lawsuits against the healthcare giant over its talc products began surfacing as early as 2009. Plaintiffs have contended that asbestos in the talc contaminated the powders and caused cancer following repeated perineal application. Johnson & Johnson has rejected these assertions, maintaining through various studies that its talc is asbestos-free and does not cause cancer. The company completed a global shift away from talc-based baby powder in 2022 after ending U.S. sales two years earlier, it said in prior statements.
A federal court provided Johnson & Johnson with a key victory in July 2026 by casting doubt on plaintiffs’ capacity to prove talc as a direct cause of cancer. Despite such rulings, the company has faced substantial adverse judgments in the past, including a 1.5 billion dollar award to a mesothelioma plaintiff in Baltimore during December 2025, according to Sokolove Law. An earlier 2018 Missouri verdict initially totaling 4.69 billion dollars for 22 ovarian cancer patients was later reduced on appeal, legal tracking services indicated. The pattern of mixed judicial results has prolonged the litigation for over 15 years.
Sokolove Law data places the total number of talcum powder lawsuits filed against Johnson & Johnson at more than 90,000 nationwide as of July 2026. Federal courts rejected the company’s two prior attempts to resolve the claims via bankruptcy, as detailed in judicial decisions. This latest settlement proposal stands as one of the largest in product liability history, plaintiffs’ attorneys noted in their announcement. Attorneys involved described the pact as providing long-sought closure for many families, in a release from Levin Papantonio.
Kenvue, which Johnson & Johnson spun off in 2022, assumed liability for talc matters outside of North America as part of the separation agreement. The parent company indicated that finalizing the settlement would enable it to concentrate resources on its pharmaceutical offerings and medical devices. Haas stated that the resolution aligns with the interests of moving past prolonged legal disputes. Johnson & Johnson expressed hope that the agreement would receive the necessary support to become effective in coming months.
